deliormanli Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) fell yesterday after the company announced that suvecaltamide failed to meet the primary endpoint in the phase 2b trial in patients with essential tremor. The company is blaming a higher placebo response, but I was not surprised by this failure. As I wrote in my January 2024 article, my expectations were low based on the available data from the previous trial. There are far more important assets and events to focus on - the performance of the comm ...